<h1>Anondita Medicare capacity expansion at Noida to add 1,360 million units annually, financed via accruals and debt, boosting compliance and market reach</h1> Approval of a large manufacturing capacity expansion at a Noida facility (~1,360 million pieces p.a.) and phased implementation with ~250 million pieces in trial production already, intended to meet rising domestic and international demand. The capital outlay (~Rs. 75 crore) will be financed through internal accruals and/or debt, affecting corporate financing and capital expenditure planning. Operational effects include automation-led efficiency gains, pursuit of UN qualification, and commercialization of patented female condom products, each enhancing regulatory compliance and market access. Financial performance metrics for H1 FY26 are disclosed. Forward-looking statements are present with a disclaimer noting risks and no obligation to update projections.